Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8910368rdf:typepubmed:Citationlld:pubmed
pubmed-article:8910368lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:8910368lifeskim:mentionsumls-concept:C1134548lld:lifeskim
pubmed-article:8910368lifeskim:mentionsumls-concept:C0010453lld:lifeskim
pubmed-article:8910368lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:8910368lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:8910368lifeskim:mentionsumls-concept:C0012472lld:lifeskim
pubmed-article:8910368lifeskim:mentionsumls-concept:C0165519lld:lifeskim
pubmed-article:8910368lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:8910368lifeskim:mentionsumls-concept:C1419063lld:lifeskim
pubmed-article:8910368lifeskim:mentionsumls-concept:C0851285lld:lifeskim
pubmed-article:8910368lifeskim:mentionsumls-concept:C0449560lld:lifeskim
pubmed-article:8910368lifeskim:mentionsumls-concept:C0205132lld:lifeskim
pubmed-article:8910368lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:8910368lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:8910368pubmed:issue44lld:pubmed
pubmed-article:8910368pubmed:dateCreated1996-12-26lld:pubmed
pubmed-article:8910368pubmed:abstractTextThe expression by T lymphocytes (T cells) of more than one of the functionally distinct subtypes of prostaglandin E2 (PGE2) receptors (Rs), designated EP1, EP2, EP3, and EP4 Rs, is a principal determinant of specificity and diversity of the immune effects of PGE2. The cultured line of human leukemic T cells, termed HSB.2, co-expresses a total of 7282 +/- 1805 EP3, EP4, and EP2 Rs per cell with a Kd of 3.7 +/- 1.4 nM (mean +/- S.E., n = 9). The EP3/EP1 R-selective agonist sulprostone, EP3/EP2/EP4 R-selective agonists M&B 28767 and misoprostol, and EP2 R-selective agonist butaprost but not the EP1 R-selective antagonist SC-19220 competitively inhibited the binding of [3H]PGE2 to HSB.2 cells. Stimulation of increases in the intracellular concentration of cyclic AMP ([cAMP]i) by PGE2, misoprostol, and butaprost and of increases in the intracellular concentration of calcium ([Ca2+]i) by PGE2 and sulprostone demonstrated the respective involvement of EP2/EP4 Rs and EP3 Rs in transduction of biochemical signals. Matrix metalloproteinase (MMP)-9 was identified by zymography and Western blots as the principal MMP secreted by HSB.2 cells. The cytosolic level and secretion of MMP-9 were increased maximally after 24 h of incubation of HSB.2 cells with 10(-8)-10(-6) M PGE2, sulprostone, M&B 28767, and misoprostol but not with 10(-6) M PGF2alpha, PGD2, PGI2, or butaprost, suggesting a principal dependence on EP3 Rs. That stimulation of MMP-9 secretion by PGE2 was not diminished in Ca2+-free medium but was suppressed significantly and dose-dependently by thapsigargin, an inhibitor of endomembrane Ca2+-ATPase, suggested that MMP-9 expression by HSB.2 cells is mediated by increases in [Ca2+]i attributable to release of Ca2+ from intracellular stores. The lack of effect of dibutyryl cAMP, forskolin, and SQ 22536, an adenylyl cyclase inhibitor, on MMP-9 secretion by HSB.2 cells argued against any role for cAMP-dependent mechanisms linked to EP2/EP4 Rs. Cycloheximide and actinomycin D, which respectively inhibited protein and RNA synthesis, suppressed basal and PGE2 induction of MMP-9 production by HSB.2 cells. Northern analysis indicated that PGE2 and sulprostone time-dependently increased expression of MMP-9 mRNA. Thus, stimulation of MMP-9 in HSB.2 T cells by PGE2 is attributable to [Ca2+]i-dependent EP3 R-mediation of increases in message transcription.lld:pubmed
pubmed-article:8910368pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:languageenglld:pubmed
pubmed-article:8910368pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:citationSubsetIMlld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8910368pubmed:statusMEDLINElld:pubmed
pubmed-article:8910368pubmed:monthNovlld:pubmed
pubmed-article:8910368pubmed:issn0021-9258lld:pubmed
pubmed-article:8910368pubmed:authorpubmed-author:GoetzlE JEJlld:pubmed
pubmed-article:8910368pubmed:authorpubmed-author:BOSSlld:pubmed
pubmed-article:8910368pubmed:authorpubmed-author:ZengLLlld:pubmed
pubmed-article:8910368pubmed:issnTypePrintlld:pubmed
pubmed-article:8910368pubmed:day1lld:pubmed
pubmed-article:8910368pubmed:volume271lld:pubmed
pubmed-article:8910368pubmed:ownerNLMlld:pubmed
pubmed-article:8910368pubmed:authorsCompleteYlld:pubmed
pubmed-article:8910368pubmed:pagination27744-50lld:pubmed
pubmed-article:8910368pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:meshHeadingpubmed-meshheading:8910368-...lld:pubmed
pubmed-article:8910368pubmed:year1996lld:pubmed
pubmed-article:8910368pubmed:articleTitleRegulation of expression of matrix metalloproteinase-9 in early human T cells of the HSB.2 cultured line by the EP3 subtype of prostaglandin E2 receptor.lld:pubmed
pubmed-article:8910368pubmed:affiliationDepartment of Medicine, University of California Medical Center, San Francisco, California 94143-0711, USA.lld:pubmed
pubmed-article:8910368pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8910368pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8910368lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8910368lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8910368lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8910368lld:pubmed